ArticleHuman cell2026
Induction of activating transcription factor 3 (ATF3) in the cerebral cortex of a mouse model of blast-induced traumatic brain injury.
Article in Human cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic brain injury (TBI) is a leading cause of long-term disabilities and mortality worldwide. Blast-induced TBI (bTBI) is the injury most commonly sustained by military personnel, but the pathomechanisms are largely unknown. Recently, accumulating evidence has suggested that neuroinflammation, characterized by the activation of microglia and astrocytes and elevated production of inflammatory mediators such as interleukins, cytokines, and chemotactic cytokines (chemokines), is a key pathological feature in bTBI. Therefore, controlling excessive neuroinflammation is critical to improve long-term neurological outcomes after bTBI, so understanding the mechanism of the neuroinflammation in bTBI is of significant interest. Activating transcription factor 3 (ATF3) is one of the most important transcription factors that regulate local and systemic inflammation in multiple pathophysiological processes such as cardiovascular disease, dementia, and ischemia/reperfusion-induced damage. Recently, ATF3 has attracted much attention for involvement in the neuroinflammatory response, by regulating the production of neuroinflammatory mediators, in a weight-drop-based TBI model. In this model, the upregulation of Atf3 messenger ribonucleic acid (mRNA) levels was rapidly induced with the strongest increase at 1-2 h and decline by 4 h post-injury. However, there is little information about ATF3 in bTBI, and thus, the present study examined the expression of ATF3 in a mouse bTBI model. We here show the significant upregulation of Atf3 mRNA was not observed in the cerebral cortex at 2 h post-exposure. However, the upregulation was observed at 5 days post-injury. Our results suggest robust differences in time course of neuroinflammation between other non-blast and blast TBIs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.